PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies

References

• AnandRGillKDMahdiAATherapeutics of Alzheimer’s disease: Past, present and futureNeuropharmacology201476Pt A275023891641
   PubMed Web of Science ®Google Scholar
• TobaJNikkuniMIshizekiMPPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer’s disease model miceBiochem Biophys Res Commun201647341039104427059136
   PubMed Web of Science ®Google Scholar
• MdSBhattmisraSKZeeshanFNano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neuro-degenerative disordersJ Drug Deliv Sci Technol201843295310
   Web of Science ®Google Scholar
• AnandAPatienceAASharmaNKhuranaNThe present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive reviewEur J Pharmacol201781536437528978455
   PubMed Web of Science ®Google Scholar
• SunDLiNZhangWDesign of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s diseaseColloids Surf B Biointerfaces201614811612927591943
   PubMed Web of Science ®Google Scholar
• Calvo-OchoaEAriasCCellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer’s disease: studies in animal modelsDiabetes Metab Res Rev2015311113
   PubMed Web of Science ®Google Scholar
• PanHChenJXuJChenMMaRAntifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblastsMol Vis2009152279228619936025
   PubMed Web of Science ®Google Scholar
• YamamotoAKakutaHMiyachiHSugimotoYInvolvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In VivoPPAR Res2011201118
   Web of Science ®Google Scholar
• ChenJLiSSunWLiJAnti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activityPLoS One2015104e01238641225875370
   PubMed Web of Science ®Google Scholar
• El-SaharAESafarMMZakiHFAttiaASAin-ShokaAANeuro-protective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkersPharmacol Rep201567590190626398383
   PubMed Web of Science ®Google Scholar
• ZolezziJMInestrosaNCPeroxisome proliferator-activated receptors and Alzheimer’s disease: hitting the blood-brain barrierMol Neurobiol201348343845123494748
   PubMed Web of Science ®Google Scholar
• NicolakakisNAboulkassimTOngaliBComplete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonistJ Neurosci200828379287929618784309
   PubMed Web of Science ®Google Scholar
• ChouPSHoBLYangYHEffects of pioglitazone on the incidence of dementia in patients with diabetesJ Diabetes Complications20173161053105728254448
   PubMed Web of Science ®Google Scholar
• LiuDLinBShaoWZhuZJiTYangCIn Vitro and in Vivo Studies on the Transport of PEGylated Silica Nanoparticles across the Blood– Brain BarrierACS Appl Mater Interfaces2014632131213624417514
   PubMed Web of Science ®Google Scholar
• MasseriniMNanoparticles for Brain Drug DeliveryISRN Biochem201320136118
   Google Scholar
• MikitshJLChackoAMPathways for small molecule delivery to the central nervous system across the blood-brain barrierPerspect Medicin Chem20146PMC.S13384
   Google Scholar
• Al AsmariAKUllahZTariqMFataniAPreparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezilDrug Des Devel Ther201610205215
   PubMedGoogle Scholar
• GromnicovaRYilmazCUOrhanNLocalization and mobility of glucose-coated gold nanoparticles within the brainNanomedicine201611661762526911484
   PubMed Web of Science ®Google Scholar
• Sánchez-LópezEEttchetoMEgeaMANew potential strategies for Alzheimer’s disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9Nanomedicine Nanotechnology. Biol Med201713311711182
   PubMed Web of Science ®Google Scholar
• PatelTZhouJPiepmeierJMSaltzmanWMPolymeric nanoparticles for drug delivery to the central nervous systemAdv Drug Deliv Rev201264770170522210134
   PubMed Web of Science ®Google Scholar
• TosiGBortotBRuoziBPotential use of polymeric nanoparticles for drug delivery across the blood-brain barrierCurr Med Chem201320172212222523458620
   PubMed Web of Science ®Google Scholar
• SalvalaioMRigonLBellettiDTargeted Polymeric Nano-particles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage DisordersPLoS One2016115e015645227228099
   PubMed Web of Science ®Google Scholar
• GuccioneCOufirMPiazziniVAndrographolide-loaded nanoparticles for brain delivery: Formulation, characterisation and in vitro permeability using hCMEC/D3 cell lineEur J Pharm Biopharm201711925326328652141
   PubMed Web of Science ®Google Scholar
• ShadapMDAliABhatnagarADesign, Development, Optimization and Characterization of Donepezil Loaded Chitosan Nanoparticles for Brain Targeting to Treat Alzheimer’s DiseaseSci Adv Mater201464720735
   Web of Science ®Google Scholar
• AraújoJVegaELopesCEgeaMAGarciaMLSoutoEBEffect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheresColloids Surf B Biointerfaces2009721485619403277
   PubMed Web of Science ®Google Scholar
• Silva-AbreuMCalpenaACEspinaMOptimization, Biopharmaceutical Profile and Therapeutic Efficacy of Pioglitazone-loaded PLGA-PEG Nanospheres as a Novel Strategy for Ocular Inflammatory DisordersPharm Res20183511129299768
   PubMed Web of Science ®Google Scholar
• AbregoGAlvaradoHSoutoEBBiopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administrationEur J Pharm Biopharm201595Pt B26127025681744
   PubMedGoogle Scholar
• XuYDuYEffect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticlesInt J Pharm2003250121522612480287
   PubMed Web of Science ®Google Scholar
• ResendeAPSilvaBBrazBSNunesTGonçalvesLDelgadoEEx vivo permeation of erythropoietin through porcine conjunctiva, cornea, and scleraDrug Deliv Transl Res20177562563128639139
   PubMed Web of Science ®Google Scholar
• GrabruckerAMRuoziBBellettiDNanoparticle transport across the blood brain barrierTissue Barriers201641e115356827141426
   PubMed Web of Science ®Google Scholar
• FessiHPuisieuxFDevissaguetJPAmmouryNBenitaSNano-capsule formation by interfacial polymer deposition following solvent displacementInt J Pharm1989551R1R4
   Web of Science ®Google Scholar
• VegaEGamisansFGarcíaMLChauvetALacouloncheFEgeaMAPLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactionsJ Pharm Sci200897125306531718425815
   PubMed Web of Science ®Google Scholar
• Silva-AbreuMEspinozaLCRodríguez-LagunasMJHuman Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory ProcessesInt J Mol Sci201718122548
   PubMed Web of Science ®Google Scholar
• MallandrichMFernández-CamposFClaresBDeveloping Transdermal Applications of Ketorolac Tromethamine Entrapped in Stimuli Sensitive Block Copolymer HydrogelsPharm Res20173481728174028540502
   PubMed Web of Science ®Google Scholar
• YamaokaKNakagawaTUnoTApplication of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJ Pharmacokinet Biopharm197862165175671222
   PubMedGoogle Scholar
• WekslerBBSubileauEAPerrièreNBlood-brain barrier-specific properties of a human adult brain endothelial cell lineFaseb J200519131872187416141364
   PubMed Web of Science ®Google Scholar
• AndreaniTKiillCPde SouzaALSurface engineering of silica nanoparticles for oral insulin delivery: characterization and cell toxicity studiesColloids Surf B Biointerfaces201412391692325466464
   PubMed Web of Science ®Google Scholar
• TaiLMHollowayKAMaleDKLoughlinAJRomeroIAAmyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activationJ Cell Mol Med20101451101111219438816
   PubMed Web of Science ®Google Scholar
• Lopez-RamirezMAWuDPryceGMicroRNA-155 negatively affects blood-brain barrier function during neuroinflammationFaseb J20142862551256524604078
   PubMed Web of Science ®Google Scholar
• BorcheltDRRatovitskiTvan LareJAccelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteinsNeuron19971949399459354339
   PubMed Web of Science ®Google Scholar
• dal MagroROrnaghiFCambianicaIApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrierJ Control Release201724910311028153761
   PubMed Web of Science ®Google Scholar
• KreuterJRamgePPetrovVDirect evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticlesPharm Res200320340941612669961
   PubMed Web of Science ®Google Scholar
• GromnicovaRKayaMRomeroIATransport of Gold Nano-particles by Vascular Endothelium from Different Human TissuesPLoS One2016118e016161027560685
   PubMed Web of Science ®Google Scholar
• ShiloMSharonABaranesKMotieiMLelloucheJPPopovtzerRThe effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell modelJ Nanobiotechnology20151311925880565
   PubMedGoogle Scholar
• FröhlichEThe role of surface charge in cellular uptake and cytotoxicity of medical nanoparticlesInt J Nanomedicine201275577559123144561
   PubMed Web of Science ®Google Scholar
• NevesARQueirozJFWekslerBRomeroIACouraudPOReisSSolid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein ENanotechnology2015264949510326574295
   PubMed Web of Science ®Google Scholar
• WohlfartSGelperinaSKreuterJTransport of drugs across the blood-brain barrier by nanoparticlesJ Control Release2012161226427321872624
   PubMed Web of Science ®Google Scholar
• SmithMWGumbletonMEndocytosis at the blood-brain barrier: from basic understanding to drug delivery strategiesJ Drug Target200614419121416777679
   PubMed Web of Science ®Google Scholar
• RejmanJOberleVZuhornISHoekstraDSize-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosisBiochem J2004377Pt 115916914505488
   PubMed Web of Science ®Google Scholar
• SearcyJLPhelpsJTPancaniTLong-Term Pioglitazone Treatment Improves Learning and Attenuates Pathological Markers in a Mouse Model of Alzheimer’s DiseaseJournal of Alzheimer’s Disease2012304943961
   PubMed Web of Science ®Google Scholar
• Mandrekar-ColucciSKarloJCLandrethGEMechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s diseaseJ Neurosci20123230101171012822836247
   PubMed Web of Science ®Google Scholar
• YinQQPeiJJXuSPioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance ratsPLoS One201383e5931323527159
   PubMed Web of Science ®Google Scholar
• PapadopoulosPRosa-NetoPRochfordJHamelEPioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer’s disease with combined amyloid-β and cerebrovascular pathologyPLoS One201387e6861223874687
   PubMed Web of Science ®Google Scholar
• TakedaExtension study of the safety and efficacy of pioglitazone to slow cognitive decline in participants with mild cognitive impairment due to Alzheimer disease Available from: https://clinicaltrials.gov/ct2/show/NCT02284906?term=pioglitazone&cond=Alzheimer+Disease&rank=3 NLM identifier: NCT02284906Accessed February 15, 2018
   Google Scholar
• Fernandez-MartosCMAtkinsonRAKChuahMIKingAEVickersJCCombination treatment with leptin and pioglitazone in a mouse model of Alzheimer’s diseaseAlzheimers Dement20173192106
   Google Scholar